Literature DB >> 12428681

Occupation of the prostaglandin E2-type 1 receptor increases rat atrial contractility via a Y-27632-sensitive pathway.

Paul E Wolkowicz1, David D Ku, Heman E Grenett, Ferdinand Urthaler.   

Abstract

This study investigated whether rat left atria (LA) contain the prostaglandin E2 type 1 receptor (EP1) and whether EP1 occupation induces positive inotropic responses in superfused LA. Western analysis demonstrated that LA contain EP1 and the EP1 splice variant. Exposing isolated, superfused LA to 17-phenyl trinor PGE2, an EP1 agonist, increased isometric contractile force and its corresponding dF/dTs to approximately 70% of the isoproterenol maximum with an EC50 of approximately 80 nM. In contrast, agonists for EP2, EP3, and EP4 caused little change in LA function. While the EP1 antagonists SC-51089 and SC-19220 blocked 17-phenyl trinor PGE2-induced inotropy, neither prazosin, nadolol, atropine nor EI-283, a pan-specific protein kinase C inhibitor, affected 17-phenyl trinor PGE2-induced inotropy. However, Y-27632 and HA-1077, inhibitors of rho A-activated protein kinases, prevented and reversed the increase in LA contractility that occurred in the presence of 17-phenyl trinor PGE2. Thus, atria contain EP1 and EP1 occupation increases LA contractility via a pathway sensitive to inhibitors of rho A-activated protein kinases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428681     DOI: 10.1016/s0090-6980(02)00014-x

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  2 in total

1.  Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor.

Authors:  Xiaosong Gu; Jiang Xu; Liping Zhu; Timothy Bryson; Xiao-Ping Yang; Edward Peterson; Pamela Harding
Journal:  Circ Heart Fail       Date:  2016-08       Impact factor: 8.790

Review 2.  Methamphetamine effects on blood-brain barrier structure and function.

Authors:  Nicole A Northrop; Bryan K Yamamoto
Journal:  Front Neurosci       Date:  2015-03-04       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.